首页> 美国卫生研究院文献>Biomarkers in Cancer >Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition
【2h】

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition

机译:癌基因:通过抑制PKR进行病毒溶瘤的护照

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The transforming properties of oncogenes are derived from gain-of-function mutations, shifting cell signaling from highly regulated homeostatic to an uncontrolled oncogenic state, with the contribution of the inactivating mutations in tumor suppressor genes P53 and RB, leading to tumor resistance to conventional and target-directed therapy. On the other hand, this scenario fulfills two requirements for oncolytic virus infection in tumor cells: inactivation of tumor suppressors and presence of oncoproteins, also the requirements to engage malignancy. Several of these oncogenes have a negative impact on the main interferon antiviral defense, the double-stranded RNA-activated protein kinase (PKR), which helps viruses to spontaneously target tumor cells instead of normal cells. This review is focused on the negative impact of overexpression of oncogenes on conventional and targeted therapy and their positive impact on viral oncolysis due to their ability to inhibit PKR-induced translation blockage, allowing virion release and cell death.
机译:癌基因的转化特性源自功能获得性突变,将细胞信号从高度调节的稳态转变为不受控制的致癌状态,并伴随着抑癌基因P53和RB失活突变的产生,导致肿瘤对常规和非常规的耐药。目标导向疗法。另一方面,这种情况满足了肿瘤细胞中溶瘤病毒感染的两个要求:抑癌剂的失活和癌蛋白的存在,以及参与恶性肿瘤的要求。这些致癌基因中的几种对主要的干扰素抗病毒防御双链RNA活化蛋白激酶(PKR)产生不利影响,该蛋白激酶帮助病毒自发靶向肿瘤细胞而不是正常细胞。这篇综述的重点是癌基因过表达对常规和靶向治疗的负面影响,以及由于其抑制PKR诱导的翻译阻滞,允许病毒体释放和细胞死亡的能力,它们对病毒溶瘤的积极影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号